Baig, N. A., Taylor, R. P., Lindorfer, M. A., Church, A. K., LaPlant, B. R., Pavey, E. S., . . . Zent, C. S. (2012). Complement dependent cytotoxicity (CDC) in chronic lymphocytic leukemia (CLL): Ofatumumab enhances alemtuzumab CDC and reveals cells resistant to activated complement. Leuk Lymphoma.
Citação norma ChicagoBaig, Nisar A., Ronald P. Taylor, Margaret A. Lindorfer, Amy K. Church, Betsy R. LaPlant, Emily S. Pavey, Grzegorz S. Nowakowski, and Clive S. Zent. "Complement Dependent Cytotoxicity (CDC) in Chronic Lymphocytic Leukemia (CLL): Ofatumumab Enhances Alemtuzumab CDC and Reveals Cells Resistant to Activated Complement." Leuk Lymphoma 2012.
Citação norma MLABaig, Nisar A., et al. "Complement Dependent Cytotoxicity (CDC) in Chronic Lymphocytic Leukemia (CLL): Ofatumumab Enhances Alemtuzumab CDC and Reveals Cells Resistant to Activated Complement." Leuk Lymphoma 2012.